What is the risk of skin cancer associated with azathioprine therapy?

Risk of Skin Cancer with Azathioprine

Azathioprine significantly increases the risk of non-melanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), with the risk rising substantially after more than 1 year of treatment—patients must be counseled about rigorous photoprotection and regular dermatologic surveillance. 1

Magnitude of Risk

The risk elevation for NMSC is clinically significant and dose/duration-dependent:

• Thiopurine use for longer than 1 year increases NMSC risk approximately 4-fold (adjusted OR 4.3; 95% CI 3.1–6.0) in inflammatory bowel disease patients 1
• Squamous cell carcinoma risk specifically increases 1.5 to 2-fold in organ transplant recipients (pooled estimate OR 1.56; 95% CI 1.11-2.18) 2
• Basal cell carcinoma risk does not appear significantly elevated (OR 0.96; 95% CI 0.66-1.40) 2
• In solid-organ transplant recipients receiving multiple immunosuppressants, NMSC risk may be elevated more than 200-fold, though azathioprine is implicated as a major contributor 1

High-Risk Populations

Certain patient groups face particularly elevated risk:

• Cumulative dose ≥500g of azathioprine increases SCC risk 30-fold (OR 30.0; 95% CI 2.6-345.1) 3
• Treatment duration ≥11 years increases SCC risk 13.5-fold (OR 13.5; 95% CI 1.3-143.6) 3
• Treatment duration ≥5 years increases SCC risk nearly 5-fold (OR 4.8; 95% CI 1.7-13.6) 4
• Organ transplant recipients already having multiple dysplastic keratoses represent the highest-risk group 1

Mechanism of Photocarcinogenesis

The carcinogenic mechanism is well-established and clinically relevant:

• 6-thioguanine (azathioprine metabolite) has maximum absorbance at 340 nm, making it highly sensitive to UVA radiation (320-400 nm), which comprises 95% of solar UV 1
• UVA photons absorbed by 6-TG-substituted DNA generate reactive oxygen species causing mutagenic DNA damage 1
• Azathioprine administration demonstrably reduces minimal erythema doses to UVA in normal skin 1

FDA-Mandated Warnings

The FDA label explicitly warns about malignancy risk:

• Patients receiving azathioprine are at increased risk of developing lymphoma and other malignancies, particularly of the skin 5
• Exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using a sunscreen with a high protection factor 5
• Post-transplant patients have known increased risk of malignancy, predominantly skin cancer 5

Clinical Management Algorithm

Patient Counseling (Before Starting Therapy)

• Inform all patients about the specific increased risk of SCC (not BCC) 1, 2
• Emphasize that risk increases substantially after 1 year of treatment and with cumulative doses 1, 3
• Explain the UV-dependent mechanism requiring rigorous photoprotection 1

Photoprotection Requirements (Mandatory for All Patients)

• Strict avoidance of direct sunlight exposure 1, 5
• High-protection factor sunscreen application (targeting UVA protection specifically) 1, 5
• Protective clothing when outdoors 1, 5

Surveillance Strategy

• Organ transplant recipients with existing dysplastic keratoses or NMSCs: Examine regularly in dedicated dermatology clinics by clinicians with skin cancer expertise 1
• All patients on azathioprine >1 year: Regular dermatologic examination for early detection 1
• Patients with cumulative dose approaching 500g or duration approaching 5 years: Intensify surveillance frequency 4, 3

Treatment Duration Considerations

• Restrict courses to short-to-medium term when possible 1
• Patients requiring long-term treatment without therapeutic alternatives: Counsel about malignancy risk but advise that if increased, it is likely small in absolute terms for internal cancers (though skin cancer risk is definitively elevated) 1

Important Caveats

The British Association of Dermatologists guidelines note that thiopurines implicate azathioprine above other immunosuppressants (MTX, mycophenolate, ciclosporin) in NMSC development, though anti-TNF agents also show association 1. This makes azathioprine a particularly concerning agent for photocarcinogenesis compared to alternative immunosuppressants.

The evidence consistently demonstrates that SCC risk is the primary concern, not BCC, which has important implications for patient education and surveillance focus 2, 3.